Francesca Corti, Maria Pia Brizzi, Vito Amoroso, Dario Giuffrida, Francesco Panzuto, Davide Campana, Natalie Prinzi, Massimo Milione, Tommaso Cascella, Carlo Spreafico, Giovanni Randon, Simone Oldani, Rita Leporati, Giulia Scotto, Iolanda Pulice, Benedetta Lombardi Stocchetti, Luca Porcu, Jorgelina Coppa, Maria Di Bartolomeo, Filippo de Braud, Sara Pusceddu
BACKGROUND: Well-differentiated (WD) neuroendocrine tumors (NETs) are a group of rare neoplasms with limited therapeutic options. Cabozantinib is an inhibitor of multiple tyrosine kinases with a pivotal role in NET pathogenesis, including c-MET and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). LOLA is the first prospective phase II trial aiming to assess the safety and activity of cabozantinib combined with lanreotide in WD NETs of gastroenteropancreatic (GEP), thoracic and of unknown origin...
September 26, 2023: BMC Cancer